On Friday, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was 6.10% up from the session before settling in for the closing price of $5.41. A 52-week range for CRVS has been $2.54 – $10.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 8.47% over the last five years. When this article was written, the company’s average yearly earnings per share was at 63.24%. With a float of $54.39 million, this company’s outstanding shares have now reached $74.51 million.
Corvus Pharmaceuticals Inc (CRVS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Corvus Pharmaceuticals Inc stocks. The insider ownership of Corvus Pharmaceuticals Inc is 27.01%, while institutional ownership is 36.89%. The most recent insider transaction that took place on Jun 27 ’25, was worth 4,891,894. In this transaction Director of this company sold 1,176,332 shares at a rate of $4.16, taking the stock ownership to the 7,165,006 shares. Before that another transaction happened on Jun 27 ’25, when Company’s Director sold 1,176,332 for $4.16, making the entire transaction worth $4,891,894. This insider now owns 7,165,006 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.6 earnings per share (EPS) during the time that was less than consensus figure (set at -0.12) by -0.48. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 63.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.52% during the next five years compared to 8.47% growth over the previous five years of trading.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
You can see what Corvus Pharmaceuticals Inc (CRVS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.02, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Analysing the last 5-days average volume posted by the [Corvus Pharmaceuticals Inc, CRVS], we can find that recorded value of 0.56 million was lower than the volume posted last year of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 70.88%.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 97.86%, which indicates a significant increase from 95.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.32 in the past 14 days, which was higher than the 0.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.52, while its 200-day Moving Average is $4.85. Now, the first resistance to watch is $5.88. This is followed by the second major resistance level at $6.02. The third major resistance level sits at $6.30. If the price goes on to break the first support level at $5.47, it is likely to go to the next support level at $5.19. Now, if the price goes above the second support level, the third support stands at $5.05.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
There are 74,514K outstanding shares of the company, which has a market capitalization of 427.71 million. As of now, sales total 0 K while income totals -62,290 K. Its latest quarter income was 0 K while its last quarter net income were -8,000 K.
